此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Differences Between Women and Men Taking a Combination of Indinavir, Ritonavir, Enteric-Coated Didanosine, and Stavudine Who Previously Took Anti-HIV Drugs

2005年6月23日 更新者:PPD

A Study of the Combination of Indinavir, Ritonavir, Enteric-Coated ddI and d4T In Nucleoside and Non-Nucleoside Reverse Transcriptase Inhibitor Experienced Patients: An Open-Label Study Investigating Differences Between Women and Men

The purpose of this study is to see how safe and effective it is to give multi-drug treatment with indinavir (IDV) plus ritonavir (RTV) plus enteric-coated didanosine (ddI) plus stavudine (d4T) and if there are differences in responses between men and women.

研究概览

详细说明

Patients are enrolled in balanced numbers based on gender and stratified by viral load (less than or equal to 10,000, 10,000 to 100,000, or more than 100,000 copies/ml). Prior to therapy, a peer-based patient education intervention is presented. Patients receive a combination of IDV, RTV, enteric-coated ddI, and d4T. Responses to this multi-agent antiretroviral drug regimen are explored based on sex differences. A pharmacokinetic sub-study, balanced so that half of patients are male and half are female, is performed on IDV and RTV for 20 to 25 of the patients. About 20 females are examined for study-drug effects on gonadotropic hormone levels.

研究类型

介入性

注册

200

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Ponce、波多黎各、00731
        • Ponce Univ Hosp
      • Rio Piedras、波多黎各、00935
        • Univ of Puerto Rico School of Med
    • California
      • Berkeley、California、美国、94705
        • East Bay AIDS Ctr
      • Los Angeles、California、美国、90095
        • UCLA CARE Ctr
      • Los Angeles、California、美国、90033
        • Univ of Southern California
    • Florida
      • Fort Lauderdale、Florida、美国、33311
        • North Broward Hosp District / HIV Clinical Research
      • Tampa、Florida、美国、33607
        • Saint Josephs Comprehensive Research Institute
    • Louisiana
      • New Orleans、Louisiana、美国、70112
        • Louisiana State Univ Med Ctr / HIV Outpatient Clinic
    • Massachusetts
      • Boston、Massachusetts、美国、02210
        • JSI Research and Training Institute
    • New Jersey
      • Newark、New Jersey、美国、07103
        • Univ of Med & Dentistry of New Jersey
    • New York
      • New York、New York、美国、10003
        • Beth Israel Med Ctr
      • New York、New York、美国、10037
        • Harlem Hosp Ctr
      • Rochester、New York、美国、14642
        • Univ of Rochester Med Ctr
    • Tennessee
      • Nashville、Tennessee、美国、37212
        • Vanderbilt Univ School of Medicine
    • Texas
      • Dallas、Texas、美国、75390
        • Univ of Texas Southwestern Med Ctr

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria

Patients may be eligible for this study if they:

  • Are HIV-positive.
  • Have viral load (amount of HIV in the blood) greater than 500 copies/ml.
  • Have received anti-HIV treatment previously with an NNRTI plus an NRTI combination or only NRTIs for greater than 8 weeks and, if not currently on treatment, have been off treatment for 12 weeks or less.
  • Failed to keep their viral load low during previous anti-HIV treatment.
  • Are at least 18 years of age.
  • Agree to use an effective barrier method of birth control.

Exclusion Criteria

Patients will not be eligible for this study if they:

  • Have used a protease inhibitor for more than 14 days.
  • Have used ddI or d4T for more than 30 days.
  • Are pregnant or breast-feeding.
  • Have an opportunistic (AIDS-related) infection requiring treatment at the time of enrollment.
  • Have, or appear to have, peripheral neuropathy (a painful condition affecting the nervous system) at the time of screening.
  • Are at risk for, or have had, pancreatitis (disease of the pancreas).
  • Have difficulty absorbing medications.
  • Have a cancer, other than Kaposi's sarcoma, that may require systemic treatment.
  • Have any medical condition or treatment that may cause a rise in viral load.
  • Have any other condition or previous treatment that would interfere with the study.
  • Are unable to take drugs by mouth.
  • Are receiving or have received recently any of the following drugs: terfenadine, astemizole, cisapride, triazolam, midazolam, ergot alkaloids, amiodarone, bepridil, flecainide, propafenone, quinidine, pimozide, rifampin, and intravenous (IV) pentamidine.
  • Are receiving vincristine, thalidomide, foscarnet, or cisplatin or other medications that may cause nerve damage.
  • Have received any experimental drug within 30 days prior to treatment.
  • Are receiving treatment with testosterone, anabolic steroids, growth hormone, or megestrol acetate, except for certain hormonal problems.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 屏蔽:无(打开标签)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

PPD

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2000年8月1日

研究注册日期

首次提交

2000年10月10日

首先提交符合 QC 标准的

2001年8月30日

首次发布 (估计)

2001年8月31日

研究记录更新

最后更新发布 (估计)

2005年6月24日

上次提交的符合 QC 标准的更新

2005年6月23日

最后验证

2001年6月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

艾滋病毒感染的临床试验

硫酸茚地那韦的临床试验

3
订阅